Oncolytics Biotech Inc. Announces Filing Of Phase 1/2 Clinical Trial With REOLYSIN

Oncolytics Biotech Inc. (”Oncolytics”) (TSX:ONC, NASDAQ:ONCY) announced that the U.S. National Cancer Institute (NCI) has filed a protocol with the U.S. Food and Drug Administration (FDA) for a Phase 1/2 clinical trial for patients with metastatic ovarian, peritoneal or fallopian tube cancers using concurrent systemic and intraperitoneal administration of REOLYSIN®, Oncolytics’ proprietary formulation of the human reovirus.

More: continued here

Filed under: Cancer on January 7th, 2008